English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

intermittent claudication/ginkgo

The link is saved to the clipboard
ArticlesClinical trialsPatents
Page 1 from 17 results

The comprehensiveness of Medline and Embase computer searches. Searches for controlled trials of homoeopathy, ascorbic acid for common cold and ginkgo biloba for cerebral insufficiency and intermittent claudication.

Only registered users can translate articles
Log In/Sign up
OBJECTIVE To assess the comprehensiveness of Medline and Embase computer searches for controlled trials. METHODS Comparison of articles found after an exhaustive search of the literature with the yield of a Medline or Embase search. This was performed for controlled clinical trials on the efficacy

Ginkgo biloba for intermittent claudication.

Only registered users can translate articles
Log In/Sign up
BACKGROUND People with intermittent claudication (IC) suffer from pain in the muscles of the leg occurring during exercise which is relieved by a short period of rest. Symptomatic relief can be achieved by (supervised) exercise therapy and pharmacological treatments. Ginkgo biloba is a vasoactive

From the Cochrane library: Ginkgo biloba for intermittent claudication.

Only registered users can translate articles
Log In/Sign up
BACKGROUND Patients with intermittent claudication suffer from pain in the muscles of the legs during exercise that is relieved by a short rest. Ginkgo biloba extract is a vasoactive agent used for symptomatic relief in intermittent claudication. In this article a meta-analysis is discussed that

Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials.

Only registered users can translate articles
Log In/Sign up
OBJECTIVE The optimal treatment of intermittent claudication has not yet been identified. Ginkgo biloba extract has been reported to have beneficial effects. We performed a meta-analysis of the efficacy of Ginkgo biloba extract for intermittent claudication based on the results of randomized,

[Ginkgo biloba in treatment of intermittent claudication. A systematic research based on controlled studies in the literature].

Only registered users can translate articles
Log In/Sign up
The aim of this systematic review was to evaluate the effectiveness of ginkgo biloba in the treatment of intermittent claudication. A Medline-search identified ten controlled trials on the subject. These were heterogeneous in all respects and, with only few exceptions, of poor methodological

[The effect of Ginkgo biloba extract in patients with intermittent claudication].

Only registered users can translate articles
Log In/Sign up
Eighteen patients with stable intermittent claudication were randomized in a double blind cross-over study comparing the effects of the Ginkgo biloba extract GB-8 at a dose of 120 mg o.d. with placebo. All patients were treated for three months with the active extract and three months with placebo.

[Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication].

Only registered users can translate articles
Log In/Sign up
This monocenter, randomized, placebo-controlled double-blind study with parallel-group comparison was carried out in order to demonstrate the efficacy of Ginkgo biloba special extract EGb 761 on objective and subjective parameters of the walking performance in trained patients suffering from

Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.

Only registered users can translate articles
Log In/Sign up
BACKGROUND A multicentric, randomized, placebo-controlled double-blind study on ginkgo biloba special extract EGb 761 (Tebonin forte) in patients suffering from peripheral occlusive arterial disease (POAD) in Fontaine stage II b was carried out in order to prove its clinical efficacy in this

Ginkgo biloba for intermittent claudication.

Only registered users can translate articles
Log In/Sign up
BACKGROUND People with intermittent claudication suffer from pain in the muscles of the leg occurring during exercise which is relieved by a short period of rest. Symptomatic relief can be achieved by (supervised) exercise therapy and pharmacological treatments. Ginkgo biloba is a vasoactive agent

Can ginkgo biloba treat intermittent claudication?

Only registered users can translate articles
Log In/Sign up

[Is Ginkgo biloba extract EGb 761 clinically effective in intermittent claudication?].

Only registered users can translate articles
Log In/Sign up

Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature.

Only registered users can translate articles
Log In/Sign up
Results from clinical trials demonstrate that standardized leaf extracts of Ginkgo biloba (SGB extract) reduce the symptoms of age-associated memory impairment and dementia, including Alzheimer's disease, and may be of benefit in treating intermittent claudication. In addition, preliminary results

[Ginkgo biloba--effect, adverse events and drug interaction].

Only registered users can translate articles
Log In/Sign up
Ginkgo is probably one of the most widely used medicinal herbs in Europe. In Norway products of ginkgo leaf extract have been approved by the Norwegian Medicines Agency for the following indication: traditionally used to improve blood circulation, for example, cold hands and feet. Elsewhere, ginkgo

[Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000].

Only registered users can translate articles
Log In/Sign up
EGb 761 is a standardized extract of dried leaves of Ginkgo biloba containing 24% ginkgo-flavonol glycosides, 6% terpene lactones such as ginkgolides A, B, C, J and bilobalide. Its broad spectrum of pharmacological activities allows it to be in adequacy to the numerous pathological

The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava.

Only registered users can translate articles
Log In/Sign up
Because use of herbal remedies is increasing, a risk-benefit profile of commonly used herbs is needed. This article provides a clinically oriented overview of the efficacy and safety of ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Wherever possible, assessments are based on
Join our facebook page

The most complete medicinal herbs database backed by science

  • Works in 55 languages
  • Herbal cures backed by science
  • Herbs recognition by image
  • Interactive GPS map - tag herbs on location (coming soon)
  • Read scientific publications related to your search
  • Search medicinal herbs by their effects
  • Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research

Google Play badgeApp Store badge